|
Carcinoma of bladder
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
Overexpression of MDM-2 mRNA and mutation of the p53 tumor suppressor gene in bladder carcinoma cell lines.
|
7619220 |
1995 |
|
Carcinoma of bladder
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Cox-Regression analysis showed a significant and independent influence of TP53 mutation on tumour progression in comparison with tumour grade, stage and history of prior bladder cancer.
|
18425359 |
2008 |
|
Carcinoma of bladder
|
0.100 |
Biomarker
|
disease |
BEFREE |
Sensitivity and specificity of p53 protein detection by immunohistochemistry in patients with urothelial bladder carcinoma.
|
18025850 |
2007 |
|
Carcinoma of bladder
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Mutations in the FGFR3 and TP53 genes have been shown to define two distinct pathways in superficial papillary and invasive UCC disease, respectively.
|
15347601 |
2005 |
|
Carcinoma of bladder
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Our results are consistent with the literature in that mutations in p53 are predominantly found in high grade bladder cancer (Odds Ratio = 4.05, Fisher Exact P = 0.104); however, the results were not statistically significant due to small numbers.
|
7957118 |
1994 |
|
Carcinoma of bladder
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We analyzed the relationship between p53 protein expression in bladder cancer tissue, p53 autoantibodies in serum and the clinical course of 32 patients with and 10 patients without transitional cell carcinoma of the urinary bladder.
|
10782026 |
2000 |
|
Carcinoma of bladder
|
0.100 |
Biomarker
|
disease |
BEFREE |
We determine how the presence or absence of p53 function impacts the cytotoxic effects of these chemotherapeutic agents in human bladder cancer.
|
11458051 |
2001 |
|
Carcinoma of bladder
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Therefore, the presence of the p53 gene mutation may provide important clues to the factors involved in bladder cancer.
|
7715016 |
1995 |
|
Carcinoma of bladder
|
0.100 |
Biomarker
|
disease |
BEFREE |
Many malignancies display amplification of MDM genes encoding negative regulators of p53 and therefore much effort to date has concentrated on the development of molecules that inhibit MDM2, the most advanced of which are being tested in clinical trials for sarcoma, glioblastoma, bladder cancer and lung adenocarcinoma.
|
28927521 |
2017 |
|
Carcinoma of bladder
|
0.100 |
Biomarker
|
disease |
BEFREE |
This study suggests that upregulated HIF1A-AS2 hampers the p53 family proteins dependent apoptotic pathway to promote Cis resistance in bladder cancer.
|
30216500 |
2019 |
|
Carcinoma of bladder
|
0.100 |
Biomarker
|
disease |
BEFREE |
MicroRNA-21 regulates proliferation and migration of bladder cancer cells and cross talk with PTEN and p53 in bladder cancer.
|
26230405 |
2015 |
|
Carcinoma of bladder
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The mutation profiles of p53 and K-ras genes in pancreatic cancer resemble that in bladder cancer rather than that in lung cancer.
|
11561602 |
2002 |
|
Carcinoma of bladder
|
0.100 |
Biomarker
|
disease |
BEFREE |
A comparison of different modes for the detection of p53 protein accumulation. A study of bladder cancer.
|
9342752 |
1997 |
|
Carcinoma of bladder
|
0.100 |
Biomarker
|
disease |
BEFREE |
We conducted a MEDLINE based literature review concerning the fundamental mechanisms of p53 and its role in the management of bladder cancer.
|
12629332 |
2003 |
|
Carcinoma of bladder
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Variants in p53 codon 72 increased the risk of bladder cancer among smokers.
|
15764300 |
2005 |
|
Carcinoma of bladder
|
0.100 |
Biomarker
|
disease |
BEFREE |
Here, we examined whether FKA could inhibit bladder cancer development and progression in vivo in the UPII-SV40T transgenic model that resembles human urothelial cell carcinoma (UCC) with defects in the p53 and the retinoblastoma (Rb) protein pathways.
|
24121102 |
2013 |
|
Carcinoma of bladder
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
To elucidate the differences in biological characteristics of bladder cancer between the two types of genetic instability, the expression of the mismatch repair (MMR) proteins, Aurora-A and p53 proteins, the number of centrosomes, numerical aberrations of chromosomes and 20q13, and DNA ploidy were examined in 100 human urothelial carcinomas of the bladder.
|
16675567 |
2006 |
|
Carcinoma of bladder
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
These results suggest that both the unique DNA binding specificity of 4-ABP and cytosine methylation contribute to the mutational spectrum of the p53 gene in human bladder cancer.
|
12009904 |
2002 |
|
Carcinoma of bladder
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
GTSE1 overexpression in bladder cancer might participate in the regulation of FoxM1/CCNB1 expression via the induction of the transfer of p53 to cytoplasm.
|
30414902 |
2019 |
|
Carcinoma of bladder
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
TP53 - molecular soldier's mutations in bladder cancer in the Kashmiri population.
|
21517233 |
2011 |
|
Carcinoma of bladder
|
0.100 |
Biomarker
|
disease |
BEFREE |
In spite of extensive literature, little is known about the role of FOXO1 and its relationship with p53 status in bladder cancer.
|
28087474 |
2017 |
|
Carcinoma of bladder
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
FGFR3 and Tp53 mutations have been proposed as defining two alternative pathways in the pathogenesis of transitional bladder cancer.
|
16061860 |
2005 |
|
Carcinoma of bladder
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The p63 and p73 expressions have been investigated in a variety of human tumours including bladder carcinomas; yet, this is the first study to simultaneously analyse the transcriptional levels of all p53 family members in bladder cancer.
|
24213852 |
2014 |
|
Carcinoma of bladder
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
However, a significantly decreased risk of bladder cancer was associated with TP53 genotypes for Arg/Arg versus Pro/Pro (odds ratio 0.74, 95% confidence interval 0.55-0.99) and Arg/Arg plus Arg/Pro versus Pro/Pro (odds ratio 0.77, 95% confidence interval 0.59-1.00) in Asians.
|
20630574 |
2010 |
|
Carcinoma of bladder
|
0.100 |
Biomarker
|
disease |
BEFREE |
Successful adenovirus-mediated wild-type p53 gene transfer in patients with bladder cancer by intravesical vector instillation.
|
11844817 |
2002 |